Kwangdong Phar (009290) - Total Liabilities
Based on the latest financial reports, Kwangdong Phar (009290) has total liabilities worth ₩608.53 Billion KRW (≈ $412.39 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Kwangdong Phar growing its equity to track the company's year-over-year net asset growth rate.
Kwangdong Phar - Total Liabilities Trend (2011–2025)
This chart illustrates how Kwangdong Phar's total liabilities have evolved over time, based on quarterly financial data. See Kwangdong Phar free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Kwangdong Phar Competitors by Total Liabilities
The table below lists competitors of Kwangdong Phar ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lollands Bank
CO:LOLB
|
Denmark | Dkr4.87 Billion |
|
BBMG Corporation
F:9BM
|
Germany | €174.70 Billion |
|
Putnam Master Intermediate Income Trust
NYSE:PIM
|
USA | $41.54 Million |
|
Exsitec Holding AB
ST:EXS
|
Sweden | Skr590.15 Million |
|
Home Center Holdings Co.Ltd
KQ:060560
|
Korea | ₩293.88 Billion |
|
Arbor Technology
TWO:3594
|
Taiwan | NT$2.37 Billion |
|
Takkt AG
XETRA:TTK
|
Germany | €359.50 Million |
|
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
|
USA | $51.12 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Kwangdong Phar's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Kwangdong Phar (009290) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kwangdong Phar's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kwangdong Phar (2011–2025)
The table below shows the annual total liabilities of Kwangdong Phar from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩608.53 Billion ≈ $412.39 Million |
+10.24% |
| 2024-12-31 | ₩552.01 Billion ≈ $374.09 Million |
+12.65% |
| 2023-12-31 | ₩490.02 Billion ≈ $332.08 Million |
+27.28% |
| 2022-12-31 | ₩384.98 Billion ≈ $260.89 Million |
+7.96% |
| 2021-12-31 | ₩356.60 Billion ≈ $241.66 Million |
+8.57% |
| 2020-12-31 | ₩328.46 Billion ≈ $222.59 Million |
-4.88% |
| 2019-12-31 | ₩345.32 Billion ≈ $234.02 Million |
+14.64% |
| 2018-12-31 | ₩301.22 Billion ≈ $204.13 Million |
-1.69% |
| 2017-12-31 | ₩306.40 Billion ≈ $207.64 Million |
+9.39% |
| 2016-12-31 | ₩280.10 Billion ≈ $189.82 Million |
-2.08% |
| 2015-12-31 | ₩286.06 Billion ≈ $193.86 Million |
+123.25% |
| 2014-12-31 | ₩128.13 Billion ≈ $86.83 Million |
-4.98% |
| 2013-12-31 | ₩134.85 Billion ≈ $91.39 Million |
+10.39% |
| 2012-12-31 | ₩122.16 Billion ≈ $82.79 Million |
+69.28% |
| 2011-12-31 | ₩72.16 Billion ≈ $48.91 Million |
-- |
About Kwangdong Phar
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti… Read more